BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schirinzi T, Garone G, Travaglini L, Vasco G, Galosi S, Rios L, Castiglioni C, Barassi C, Battaglia D, Gambardella ML, Cantonetti L, Graziola F, Marras CE, Castelli E, Bertini E, Capuano A, Leuzzi V. Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. Parkinsonism Relat Disord 2019;61:19-25. [PMID: 30642806 DOI: 10.1016/j.parkreldis.2018.11.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Savitsky M, Solis GP, Kryuchkov M, Katanaev VL. Humanization of Drosophila Gαo to Model GNAO1 Paediatric Encephalopathies. Biomedicines 2020;8:E395. [PMID: 33036271 DOI: 10.3390/biomedicines8100395] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gonzalez-latapi P, Marotta N, Mencacci NE. Emerging and converging molecular mechanisms in dystonia. J Neural Transm 2021;128:483-98. [DOI: 10.1007/s00702-020-02290-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
3 Baizabal-carvallo JF, Cardoso F. Chorea in children: etiology, diagnostic approach and management. J Neural Transm 2020;127:1323-42. [DOI: 10.1007/s00702-020-02238-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Akasaka M, Kamei A, Tanifuji S, Asami M, Ito J, Mizuma K, Oyama K, Tokutomi T, Yamamoto K, Fukushima A, Takenouchi T, Uehara T, Suzuki H, Kosaki K. GNAO1 mutation-related severe involuntary movements treated with gabapentin. Brain Dev 2021;43:576-9. [PMID: 33358199 DOI: 10.1016/j.braindev.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Fung EL, Mo C, Fung ST, Chan AY, Lau K, Chan EK, Chan DY, Zhu X, Chan DT, Poon W. Deep brain stimulation in a young child with GNAO1 mutation – Feasible and helpful. Surgical Neurology International 2022;13:285. [DOI: 10.25259/sni_166_2022] [Reference Citation Analysis]
6 Schirinzi T, Landi D, Liguori C. COVID-19: dealing with a potential risk factor for chronic neurological disorders. J Neurol 2021;268:1171-8. [PMID: 32852580 DOI: 10.1007/s00415-020-10131-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Yang X, Niu X, Yang Y, Cheng M, Zhang J, Chen J, Yang Z, Zhang Y. Phenotypes of GNAO1 Variants in a Chinese Cohort. Front Neurol 2021;12:662162. [PMID: 34122306 DOI: 10.3389/fneur.2021.662162] [Reference Citation Analysis]
8 Muntean BS, Masuho I, Dao M, Sutton LP, Zucca S, Iwamoto H, Patil DN, Wang D, Birnbaumer L, Blakely RD, Grill B, Martemyanov KA. Gαo is a major determinant of cAMP signaling in the pathophysiology of movement disorders. Cell Rep 2021;34:108718. [PMID: 33535037 DOI: 10.1016/j.celrep.2021.108718] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Graziola F, Garone G, Grasso M, Capuano A. Cognitive Assessment in GNAO1 Neurodevelopmental Disorder Using an Eye Tracking System. J Clin Med 2021;10:3541. [PMID: 34441836 DOI: 10.3390/jcm10163541] [Reference Citation Analysis]
10 Wirth T, Garone G, Kurian MA, Piton A, Millan F, Telegrafi A, Drouot N, Rudolf G, Chelly J, Marks W, Burglen L, Demailly D, Coubes P, Castro-Jimenez M, Joriot S, Ghoumid J, Belin J, Faucheux JM, Blumkin L, Hull M, Parnes M, Ravelli C, Poulen G, Calmels N, Nemeth AH, Smith M, Barnicoat A, Ewenczyk C, Méneret A, Roze E, Keren B, Mignot C, Beroud C, Acosta F Jr, Nowak C, Wilson WG, Steel D, Capuano A, Vidailhet M, Lin JP, Tranchant C, Cif L, Doummar D, Anheim M. Highlighting the Dystonic Phenotype Related to GNAO1. Mov Disord 2022. [PMID: 35722775 DOI: 10.1002/mds.29074] [Reference Citation Analysis]
11 McTague A, Brunklaus A, Barcia G, Varadkar S, Zuberi SM, Chatron N, Parrini E, Mei D, Nabbout R, Lesca G. Defining causal variants in rare epilepsies: An essential team effort between biomedical scientists, geneticists and epileptologists. Eur J Med Genet 2022;:104531. [PMID: 35618197 DOI: 10.1016/j.ejmg.2022.104531] [Reference Citation Analysis]
12 Solis GP, Kozhanova TV, Koval A, Zhilina SS, Mescheryakova TI, Abramov AA, Ishmuratov EV, Bolshakova ES, Osipova KV, Ayvazyan SO, Lebon S, Kanivets IV, Pyankov DV, Troccaz S, Silachev DN, Zavadenko NN, Prityko AG, Katanaev VL. Pediatric Encephalopathy: Clinical, Biochemical and Cellular Insights into the Role of Gln52 of GNAO1 and GNAI1 for the Dominant Disease. Cells 2021;10:2749. [PMID: 34685729 DOI: 10.3390/cells10102749] [Reference Citation Analysis]
13 Galosi S, Nardecchia F, Leuzzi V. Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features. Mov Disord Clin Pract 2020;7:154-66. [PMID: 32071932 DOI: 10.1002/mdc3.12897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Liu Y, Zhang Q, Wang J, Liu J, Yang W, Yan X, Ouyang Y, Yang H. Both subthalamic and pallidal deep brain stimulation are effective for GNAO1 -associated dystonia: three case reports and a literature review. Ther Adv Neurol Disord 2022;15:175628642210935. [DOI: 10.1177/17562864221093507] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lange LM, Gonzalez-Latapi P, Rajalingam R, Tijssen MAJ, Ebrahimi-Fakhari D, Gabbert C, Ganos C, Ghosh R, Kumar KR, Lang AE, Rossi M, van der Veen S, van de Warrenburg B, Warner T, Lohmann K, Klein C, Marras C; on behalf of the Task Force on Genetic Nomenclature in Movement Disorders. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. Mov Disord 2022. [PMID: 35481685 DOI: 10.1002/mds.28982] [Reference Citation Analysis]
16 Keller Sarmiento IJ, Mencacci NE. Genetic Dystonias: Update on Classification and New Genetic Discoveries. Curr Neurol Neurosci Rep 2021;21:8. [PMID: 33564903 DOI: 10.1007/s11910-021-01095-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Moreno-De-Luca A, Millan F, Pesacreta DR, Elloumi HZ, Oetjens MT, Teigen C, Wain KE, Scuffins J, Myers SM, Torene RI, Gainullin VG, Arvai K, Kirchner HL, Ledbetter DH, Retterer K, Martin CL. Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy. JAMA 2021;325:467-75. [PMID: 33528536 DOI: 10.1001/jama.2020.26148] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 22.0] [Reference Citation Analysis]
18 Silachev D, Koval A, Savitsky M, Padmasola G, Quairiaux C, Thorel F, Katanaev VL. Mouse models characterize GNAO1 encephalopathy as a neurodevelopmental disorder leading to motor anomalies: from a severe G203R to a milder C215Y mutation. Acta Neuropathol Commun 2022;10:9. [PMID: 35090564 DOI: 10.1186/s40478-022-01312-z] [Reference Citation Analysis]
19 Cif L, Demailly D, Lin JP, Barwick KE, Sa M, Abela L, Malhotra S, Chong WK, Steel D, Sanchis-Juan A, Ngoh A, Trump N, Meyer E, Vasques X, Rankin J, Allain MW, Applegate CD, Attaripour Isfahani S, Baleine J, Balint B, Bassetti JA, Baple EL, Bhatia KP, Blanchet C, Burglen L, Cambonie G, Seng EC, Bastaraud SC, Cyprien F, Coubes C, d'Hardemare V, Doja A, Dorison N, Doummar D, Dy-Hollins ME, Farrelly E, Fitzpatrick DR, Fearon C, Fieg EL, Fogel BL, Forman EB, Fox RG, Gahl WA, Galosi S, Gonzalez V, Graves TD, Gregory A, Hallett M, Hasegawa H, Hayflick SJ, Hamosh A, Hully M, Jansen S, Jeong SY, Krier JB, Krystal S, Kumar KR, Laurencin C, Lee H, Lesca G, François LL, Lynch T, Mahant N, Martinez-Agosto JA, Milesi C, Mills KA, Mondain M, Morales-Briceno H, Ostergaard JR, Pal S, Pallais JC, Pavillard F, Perrigault PF, Petersen AK, Polo G, Poulen G, Rinne T, Roujeau T, Rogers C, Roubertie A, Sahagian M, Schaefer E, Selim L, Selway R, Sharma N, Signer R, Soldatos AG, Stevenson DA, Stewart F, Tchan M, Verma IC, de Vries BBA, Wilson JL, Wong DA, Zaitoun R, Zhen D, Znaczko A, Dale RC, de Gusmão CM, Friedman J, Fung VSC, King MD, Mohammad SS, Rohena L, Waugh JL, Toro C, Raymond FL, Topf M, Coubes P, Gorman KM, Kurian MA; Deciphering Developmental Disorders Study., Genomics England Research Consortium., NIHR BioResource., Undiagnosed Diseases Network. KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain 2020;143:3242-61. [PMID: 33150406 DOI: 10.1093/brain/awaa304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
20 Jinnah H, Sun YV. Dystonia genes and their biological pathways. Neurobiology of Disease 2019;129:159-68. [DOI: 10.1016/j.nbd.2019.05.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
21 Malaquias MJ, Fineza I, Loureiro L, Cardoso L, Alonso I, Magalhães M. GNAO1 mutation presenting as dyskinetic cerebral palsy. Neurol Sci 2019;40:2213-6. [PMID: 31190250 DOI: 10.1007/s10072-019-03964-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Graziola F, Garone G, Stregapede F, Bosco L, Vigevano F, Curatolo P, Bertini E, Travaglini L, Capuano A. Diagnostic Yield of a Targeted Next-Generation Sequencing Gene Panel for Pediatric-Onset Movement Disorders: A 3-Year Cohort Study. Front Genet 2019;10:1026. [PMID: 31737037 DOI: 10.3389/fgene.2019.01026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
23 Xu S, Yu W, Zhang X, Wang W, Wang X. The regulatory role of Gnao1 protein in diabetic encephalopathy in KK-Ay mice and streptozotocin-induced diabetic rats. Brain Res 2022;1792:148012. [PMID: 35839930 DOI: 10.1016/j.brainres.2022.148012] [Reference Citation Analysis]
24 Di Rocco M, Galosi S, Lanza E, Tosato F, Caprini D, Folli V, Friedman J, Bocchinfuso G, Martire A, Di Schiavi E, Leuzzi V, Martinelli S. Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia. Hum Mol Genet 2021:ddab296. [PMID: 34622282 DOI: 10.1093/hmg/ddab296] [Reference Citation Analysis]
25 Wang D, Dao M, Muntean BS, Giles AC, Martemyanov KA, Grill B. Genetic modeling of GNAO1 disorder delineates mechanisms of Gαo dysfunction. Hum Mol Genet 2021:ddab235. [PMID: 34508586 DOI: 10.1093/hmg/ddab235] [Reference Citation Analysis]